Home > Insider Trading > Filing (0001012975-13-000127)

Filing Details

Accession Number:: 0001012975-13-000127
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-03-28 17:19:20
Reporting Period:: 2013-03-26

Filing Date:: 2013-03-28
Accepted Time:: 2013-03-28 17:19:20
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1177648	Enanta Pharmaceuticals Inc	ENTA	Pharmaceutical Preparations (2834)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1133921	Helmut Schuhsler	C/O Tvm Capital Maximilianstrasse 35C Munich 2M 80539		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-03-26	236,065	$0.00	236,065	No	4	C	Indirect	See Note 5.
Common Stock	Acquisiton	2013-03-26	351,014	$0.00	587,079	No	4	C	Indirect	See Note 6.
Common Stock	Acquisiton	2013-03-26	155,316	$0.00	742,395	No	4	C	Indirect	See Note 5.
Common Stock	Acquisiton	2013-03-26	172,030	$0.00	914,425	No	4	C	Indirect	See Note 6.
Common Stock	Acquisiton	2013-03-26	1,006,498	$0.00	1,920,923	No	4	C	Indirect	See Note 7.
Common Stock	Acquisiton	2013-03-26	478,247	$0.00	2,399,170	No	4	C	Indirect	See Note 7.
Common Stock	Acquisiton	2013-03-26	132,949	$14.00	2,532,119	No	4	P	Indirect	See Note 7.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Note 5.
No	4	C	Indirect	See Note 6.
No	4	C	Indirect	See Note 5.
No	4	C	Indirect	See Note 6.
No	4	C	Indirect	See Note 7.
No	4	C	Indirect	See Note 7.
No	4	P	Indirect	See Note 7.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series C Convertible Preferred Stock	Disposition	2013-03-26	1,017,442	$0.00	236,065	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2013-03-26	1,130,000	$0.00	351,014	$0.00
Common Stock	Series D Convertible Preferred Stock	Disposition	2013-03-26	500,000	$0.00	155,316	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2013-03-26	563,503	$0.00	172,030	$0.00
Common Stock	Series E Convertible Preferred Stock	Disposition	2013-03-26	3,296,888	$0.00	1,006,498	$0.00
Common Stock	Series G-2 Convertible Preferred Stock	Disposition	2013-03-26	2,061,246	$0.00	478,247	$0.00

Remaning Holdings	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0	No	4	C	Indirect
500,000	No	4	C	Indirect
0	No	4	C	Indirect
3,296,888	No	4	C	Indirect
0	No	4	C	Indirect
0	No	4	C	Indirect

Footnotes

The Series C Convertible Preferred Stock automatically converted into Enanta Pharmaceuticals, Inc. ("Enanta") Common Stock on a 0.23202-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.
The Series D Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.31063-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.
The Series E Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.30529-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.
The Series G-2 Convertible Preferred Stock automatically converted into Enanta Common Stock on a 0.23202-for-one basis automatically upon the closing of the initial public offering of Enanta without payment of further consideration and had no expiration date.
The shares are directly held by TVM Medical Ventures GmbH & Co. KG ("Medical Ventures"), the general partner of which is TVM Capital GmbH ("TVM Capital"), for which Helmut Schuhsler ("Schuhsler"), one member of the investment committee of TVM Capital, shares voting and investment authority over the shares held by Medical Ventures with the other member of the investment committee. Schuhsler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
The shares are directly held by TVM IV GmbH & Co. KG ("TVM IV"), the managing limited partner of which is TVM IV Management GmbH & Co. KG ("TVM IV Management"), for which Schuhsler, one member of the investment committee of TVM IV Management, shares voting and investment authority over the shares held by TVM IV with the other members of the investment committee. Schuhsler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
The shares are directly held by TVM V Life Science Ventures GmbH & Co. KG ("TVM V"), the managing limited partner of which is TVM V Life Science Ventures Management GmbH & Co. KG ("TVM V Management"), for which for which Schuhsler, one member of the investment committee of TVM V Management, shares voting and investment authority over the shares held by TVM V with the other members of the investment committee. Schuhsler disclaims beneficial ownership of these shares except to the extent of his pecuniary interest therein, if any.
Includes 236,065 shares held directly by Medical Ventures.
Includes 236,065 shares held directly by Medical Ventures and 351,014 shares held directly by TVM IV.
Includes 391,381 shares held directly by Medical Ventures and 351,014 shares held directly by TVM IV.
Includes 391,381 shares held directly by Medical Ventures and 523,044 shares held directly by TVM IV.
Includes 391,381 shares held directly by Medical Ventures, 523,044 shares held directly by TVM IV and 1,006,498 shares held directly by TVM V.
Includes 391,381 shares held directly by Medical Ventures, 523,044 shares held directly by TVM IV and 1,484,745 shares held directly by TVM V.
Includes 391,381 shares held directly by Medical Ventures, 523,044 shares held directly by TVM IV and 1,617,694 shares held directly by TVM V.